{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:34:14Z","timestamp":1793046854733,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023280","name":"Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omta.2026.201850","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:43:57Z","timestamp":1790034237000},"page":"201850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["pSIM: A next generation in vitro mRNA potency assay"],"prefix":"10.1016","volume":"34","author":[{"given":"Marissa K.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hima","family":"Sapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Schutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveen","family":"Rathnasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8199-7970","authenticated-orcid":false,"given":"Jiang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201850_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201850_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omta.2026.201850_bib3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jmv.27424","article-title":"Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database","volume":"94","author":"Kim","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omta.2026.201850_bib4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omta.2026.201850_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","article-title":"Structures and functions of coronavirus replication\u2013transcription complexes and their relevance for SARS-CoV-2 drug design","volume":"23","author":"Malone","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201850_bib6","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omta.2026.201850_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.omtm.2022.09.013","article-title":"Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets","volume":"27","author":"Chang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201850_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201850_bib9","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201850_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.omtm.2022.03.013","article-title":"Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models","volume":"25","author":"Palladino","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201850_bib11","article-title":"First self-amplifying mRNA vaccine approved","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201850_bib12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/vaccines11071224","article-title":"Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA\u2013LNP-Based Vaccines","volume":"11","author":"Patel","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.omta.2026.201850_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","article-title":"Considerations for bioanalytical characterization and batch release of COVID-19 vaccines","volume":"6","author":"Sanyal","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omta.2026.201850_bib14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/vaccines12070714","article-title":"Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern","volume":"12","author":"Kumari","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.omta.2026.201850_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-023-36110-1","article-title":"Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models","volume":"14","author":"Corleis","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201850_bib16","article-title":"A novel in-vitro expression assay by LC\/MS\/MS enables multi-antigen mRNA vaccine characterization","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201850_bib17","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1016\/j.vaccine.2023.04.044","article-title":"Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry","volume":"41","author":"Sutton","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.omta.2026.201850_bib18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.vaccine.2011.12.056","article-title":"Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry","volume":"30","author":"Williams","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.omta.2026.201850_bib19","doi-asserted-by":"crossref","first-page":"12842","DOI":"10.1021\/acs.analchem.3c02048","article-title":"The CombE-IDMS Assay as an Alternate Potency Method for Adjuvanted Quadrivalent Influenza Vaccines","volume":"95","author":"Qian","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omta.2026.201850_bib20","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1016\/j.vaccine.2021.07.066","article-title":"Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry","volume":"39","author":"Pierce-Ruiz","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.omta.2026.201850_bib21","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1016\/j.vaccine.2018.08.065","article-title":"Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination","volume":"36","author":"Morgenstern","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.omta.2026.201850_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/978-3-030-15950-4_34","article-title":"Pulse SILAC Approaches to the Measurement of Cellular Dynamics","volume":"1140","author":"Snider","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omta.2026.201850_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1074\/mcp.M200025-MCP200","article-title":"Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics","volume":"1","author":"Ong","year":"2002","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omta.2026.201850_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-022-00478-w","article-title":"Rational development of a combined mRNA vaccine against COVID-19 and influenza","volume":"7","author":"Ye","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omta.2026.201850_bib25","article-title":"Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201850_bib26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtm.2020.12.007","article-title":"Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus","volume":"20","author":"Fu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201850_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.omta.2026.201850_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pst.2408","article-title":"Potency Assay Variability Estimation in Practice","volume":"24","author":"Li","year":"2025","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.omta.2026.201850_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106671","article-title":"Large inherent variability in data derived from highly standardised cell culture experiments","volume":"188","author":"Reddin","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omta.2026.201850_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41120-025-00125-3","article-title":"Impact of cell line and reporter gene selection on in-vitro transfection evaluation of mRNA lipid nanoparticles","volume":"11","author":"Zhen","year":"2025","journal-title":"AAPS Open"},{"key":"10.1016\/j.omta.2026.201850_bib31","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ymthe.2019.07.018","article-title":"Endocytic Profiling of Cancer Cell Models Reveals Critical Factors Influencing LNP-Mediated mRNA Delivery and Protein Expression","volume":"27","author":"Sayers","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201850_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/pmic.200400941","article-title":"Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies","volume":"5","author":"Ferguson","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.omta.2026.201850_bib33","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omta.2026.201850_bib34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the Cold Reality of mRNA Vaccine Stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omta.2026.201850_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omta.2026.201850_bib36","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201850_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s42004-025-01699-5","article-title":"Spotlighting the criticality of lipid quality control through a mechanistic investigation of mRNA activity loss in lipid nanoparticles","volume":"8","author":"Kang","year":"2025","journal-title":"Commun. Chem."},{"key":"10.1016\/j.omta.2026.201850_bib38","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1038\/s41467-025-63651-4","article-title":"Buffer optimization of siRNA-lipid nanoparticles mitigates lipid oxidation and RNA-lipid adduct formation","volume":"16","author":"Estabrook","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201850_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102684","article-title":"Analytical approach for identification and mechanistic insights into mRNA-lipid adduct formation","volume":"36","author":"Peronin","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omta.2026.201850_bib40","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.45.2400196","article-title":"Post-disappearance scenarios: policy implications following the potential disappearance of B\/Yamagata lineage influenza viruses","volume":"29","author":"Del Riccio","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.omta.2026.201850_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41541-024-01010-y","article-title":"Implications of the apparent extinction of B\/Yamagata-lineage human influenza viruses","volume":"9","author":"Barr","year":"2024","journal-title":"npj Vaccines"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:37:13Z","timestamp":1793043433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S3117387X26001850"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201850","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"pSIM: A next generation in vitro mRNA potency assay","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201850"}}